Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cytarabine 4Cyclophosphamide 4Amifostine 4Etoposide 3sargramostim 2Voriconazole 2Radiotherapy 2Methotrexate 2pegaspargase 1glucarpidase 1Vincristine 1Silymarin 1Pyridostigmine Bromide 1Prednisolone 1Phenobarbital 1Mitoxantrone 1Methylprednisolone 1Mercaptopurine 1Leucovorin 1Irinotecan 1Ifosfamide 1Idarubicin 1Hydrocortisone 1Filgrastim 1Fibroblast Growth Factor 7 1Epoetin Alfa 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Deoxycytidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Silymarin × Other hematologic neoplasm × Clear all
NCT00055718 2013-12-18

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡